Organon and Co

NCT05264506

Phase 3Terminated20223,055 people3 Mar 2022clinicaltrials.gov

NCT03885921

Phase 3Completed200044 people22 Mar 2019clinicaltrials.gov

NCT03884452

Phase 3Completed200050 people21 Mar 2019clinicaltrials.gov

NCT03882996

Phase 3Completed2000432 people20 Mar 2019clinicaltrials.gov

NCT03882905

Phase 3Completed2001769 people20 Mar 2019clinicaltrials.gov

NCT03882892

Phase 3Completed2001400 people20 Mar 2019clinicaltrials.gov

NCT03867318

Phase 3Completed2000621 people7 Mar 2019clinicaltrials.gov

NCT03867110

Phase 3Completed2000628 people7 Mar 2019clinicaltrials.gov

NCT03768427

Phase 3Completed2019454 people7 Dec 2018clinicaltrials.gov

NCT02748057

Phase 3Completed2016135 people22 Apr 2016clinicaltrials.gov

NCT02741245

Phase 3Completed2016321 people18 Apr 2016clinicaltrials.gov

NCT02550288

Phase 3Completed2015309 people15 Sept 2015clinicaltrials.gov

NCT01723579

Phase 3Withdrawn20130 people8 Nov 2012clinicaltrials.gov

NCT01709318

Phase 2Completed2012666 people18 Oct 2012clinicaltrials.gov

NCT01617187

Phase 3Completed2012360 people12 Jun 2012clinicaltrials.gov

NCT01611883

Phase 4Completed2012152 people5 Jun 2012clinicaltrials.gov

NCT01599494

Phase 3Withdrawn20140 people16 May 2012clinicaltrials.gov

NCT01587235

Phase 4Withdrawn20130 people30 Apr 2012clinicaltrials.gov

NCT01554163

Phase 3Completed2012239 people14 Mar 2012clinicaltrials.gov

NCT01370603

Phase 3Completed2011328 people10 Jun 2011clinicaltrials.gov